TherapeuticsMD, Inc. (TXMD)

Market Cap	24.54M +51.5%
Revenue (ttm)	3.35M +82.1%
Net Income	179,000
EPS	0.02
Shares Out	11.57M
PE Ratio	285.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,391
Open	2.150
Previous Close	2.110
Day's Range	2.040 - 2.150
52-Week Range	0.981 - 2.950
Beta	0.58
Analysts	Hold
Price Target	5.00 (+135.85%)
Earnings Date	May 12, 2026

About TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: TXMD
• Website: https://www.therapeuticsmd.com

Financial Performance

In 2025, TherapeuticsMD's revenue was $3.02 million, an increase of 71.61% compared to the previous year's $1.76 million. Losses were -$569,000, -73.91% less than in 2024.

Analyst Summary

According to one analyst, the rating for TXMD stock is "Hold" and the 12-month stock price target is $5.0.

Price Target

$5.0

(135.85% upside)

Analyst Consensus: Hold